Komori
Zeria Pharmaceutical (4559) · PolicyRestated

Application of IFRS 16, “Leases,” to Overseas Consolidated Subsidiaries

First written in FY2020-Q1. 2 of 3 entries say "Restated". Latest entry: FY2020-Q3.

3entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2020-Q1 – FY2020-Q32019: 220192020: 12020
Same theme, other companies

The whole theme swung hardest in 2025: 4 of 17 companies on the "Worse" side.

107 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 178 companies compared. The sentences above are computed from all 178.
Full recordFilings, disclosures and news, newest first
  1. FY2020-Q3RestatedAnnual report

    「An overseas consolidated subsidiary has applied IFRS 16, Leases, from the beginning of the first quarter of the current consolidated fiscal year. As a result of applying the accounting standard, as of the beginning of the first quarter of the current consolidated fiscal year, other property, plant and equipment increased by ¥881.256 million, other current liabilities increased by ¥221.534 million, and other non-current liabilities increased by ¥659.722 million. The impact of this change on profit or loss for the cumulative third quarter of the current consolidated fiscal year was immaterial.」

    The company continues to explain the application of IFRS 16 to an overseas consolidated subsidiary, the resulting increases in assets and liabilities, and the immaterial impact on profit or loss.
  2. FY2020-Q2RestatedAnnual report

    「An overseas consolidated subsidiary has applied IFRS 16, Leases, from the beginning of the first quarter of the current consolidated fiscal year. As a result of applying the accounting standard, as of the beginning of the first quarter of the current consolidated fiscal year, other property, plant and equipment increased by ¥881.256 million, other current liabilities increased by ¥221.534 million, and other non-current liabilities increased by ¥659.722 million. The impact of this change on profit or loss for the cumulative second quarter of the current consolidated fiscal year was immaterial.」

    The company continues to explain the application of IFRS 16 to an overseas consolidated subsidiary, the resulting increases in assets and liabilities, and the immaterial impact on profit or loss.
  3. FY2020-Q1First statedAnnual report

    「An overseas consolidated subsidiary has applied IFRS 16, Leases, from the beginning of the first quarter of the current consolidated fiscal year. As a result of applying the accounting standard, as of the beginning of the first quarter of the current consolidated fiscal year, other property, plant and equipment increased by ¥881.256 million, other current liabilities increased by ¥221.534 million, and other non-current liabilities increased by ¥659.722 million. The impact of this change on profit or loss for the cumulative first quarter of the current consolidated fiscal year was immaterial.」

    An overseas consolidated subsidiary applied IFRS 16 from 1 April 2019, increasing the amounts recognised for property, plant and equipment and liabilities. The company explained that the impact on profit or loss was immaterial.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Zeria Pharmaceutical's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Application of IFRS 16, “Leases,” to Overseas Consolidated Subsidiaries | ZERIA PHARMACEUTICAL CO.,LTD. (4559) | Komori